Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of an extended-spectrum penicillin (piperacillin) and a beta-lactamase inhibitor (tazobactam). It is active against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Empirical treatment of febrile neutropenia (in combination with an aminoglycoside)
## Adult Dosing
Standard dose: 3.375 g intravenously every 6 hours or 4.5 g intravenously every 8 hours.
* Dosing frequency and duration depend on the severity of infection, renal function, and pathogen susceptibility.
* Higher doses may be used for severe infections or nosocomial pneumonia.
## Pediatric Dosing
* Children < 12 years old: 100 mg piperacillin / 12.5 mg tazobactam per kg per dose intravenously every 8 hours. Maximum dose: 3.375 g per dose.
* Children and adolescents > 12 years old: Same adult dosing.
* Dosing in neonates and infants < 12 months is less established and should be guided by clinical judgment and renal function.
## Dose Adjustments
Dose reduction or increased dosing interval is required for renal impairment.
* CrCl 20-40 mL/min: 2.25 g IV q6h or 3.375 g IV q8h.
* CrCl < 20 mL/min: 2.25 g IV q8h or 3.375 g IV q12h.
* Hemodialysis: Administer dose, then administer an additional 0.75 g dose after each dialysis period.
* Hepatic impairment: No specific dose adjustment is generally recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactam antibiotics.
* History of immediate and severe hypersensitivity reactions (e.g., anaphylaxis) to piperacillin, tazobactam, or other beta-lactams.
## Adverse Effects
Common: Diarrhea, rash, nausea, vomiting, headache, insomnia, fever.
Serious:
* Hypersensitivity reactions including anaphylaxis.
* Clostridioides difficile-associated diarrhea.
* Seizures (more common with high doses or renal impairment).
* Hematologic effects (e.g., neutropenia, thrombocytopenia).
* Hepatotoxicity.
## Key Drug Interactions
* Probenecid: May increase piperacillin-tazobactam serum concentrations.
* Neuromuscular blocking agents (e.g., vecuronium): May prolong neuromuscular blockade.
* Warfarin: May decrease the anticoagulant effect of warfarin.
* Methotrexate: May decrease methotrexate serum concentrations.
## Monitoring
* Renal function (CrCl) for dose adjustments.
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of C. difficile infection.
* Complete blood count (CBC) with differential if therapy is prolonged.
* Liver function tests if therapy is prolonged or in patients with hepatic disease.
## Clinical Pearls
* Piperacillin-tazobactam has a broad spectrum of activity, including many resistant organisms like Pseudomonas aeruginosa.
* It should be reconstituted and diluted according to manufacturer guidelines.
* Infusion rate is crucial to minimize adverse effects. Extended infusions (e.g., over 4 hours) may be associated with improved outcomes and reduced toxicity in some populations.
* Culture and susceptibility testing should be performed before initiating treatment and periodically thereafter to guide therapy.
* Discontinue if hypersensitivity reaction or C. difficile diarrhea occurs.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant guidelines for complete and up-to-date details.*
